Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders. The company is headquartered in Audubon, Pennsylvania.
| Revenue (TTM) | $3.14B |
| Gross Profit (TTM) | $2.19B |
| EBITDA | $1.06B |
| Operating Margin | 23.30% |
| Return on Equity | 12.10% |
| Return on Assets | 9.18% |
| Revenue/Share (TTM) | $23.30 |
| Book Value | $36.15 |
| Price-to-Book | 2.29 |
| Price-to-Sales (TTM) | 3.04 |
| EV/Revenue | 3.323 |
| EV/EBITDA | 10.96 |
| Quarterly Earnings Growth (YoY) | 18.20% |
| Quarterly Revenue Growth (YoY) | -0.70% |
| Shares Outstanding | $111.83M |
| Float | $109.60M |
| % Insiders | 0.61% |
| % Institutions | 95.44% |
Volatility is currently expanding
Globus Medical cuts its 2026 revenue outlook amid spine launch delays and weak Nevro sales while shifting its focus to new products and growth opportunities in 2027.
AUDUBON, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the third quarter ended September 30, 2026.
Globus Medical is leveraging flexible leasing models to expand its installed base, prioritizing recurring high-margin implant sales over upfront capital revenue. GMED's post-NuVasive integration is driving structurally higher margins, with adjusted EBITDA margins rising to 35.4% and free cash flow nearly doubling year-over-year. Despite a segment revenue decline, ExcelsiusGPS placements grew 25%, supporting a transition to a more recurring, cash-generative business model.
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and AxoGen (AXGN). But which of these two companies is the best option for those looking for undervalued stocks?
The consensus price target hints at a 30.5% upside potential for Globus Medical (GMED). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GMED and STE offer exposure to healthcare technology growth, with projected 2026 EPS gains, attractive valuations and innovations in essential medical services.
NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Globus Medical, Inc. (NYSE: GMED) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or AxoGen (AXGN). But which of these two stocks offers value investors a better bang for their buck right now?
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GMED and any ticker you trade — then tracks every position and per-strategy win rate.
